Intercept Pharmaceuticals Inc (ICPT): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Intercept Pharmaceuticals ( ICPT) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 0.7%. By the end of trading, Intercept Pharmaceuticals fell $20.06 (-5.5%) to $346.51 on light volume. Throughout the day, 546,164 shares of Intercept Pharmaceuticals exchanged hands as compared to its average daily volume of 770,200 shares. The stock ranged in price between $342.70-$373.85 after having opened the day at $367.51 as compared to the previous trading day's close of $366.57. Other companies within the Drugs industry that declined today were: Ohr Pharmaceutical ( OHRP), down 18.9%, Galena Biopharma ( GALE), down 14.3%, Tianyin Pharmaceutical ( TPI), down 13.1% and Prana Biotechnology ( PRAN), down 10.9%.

Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat chronic liver diseases utilizing its proprietary bile acid chemistry. Intercept Pharmaceuticals has a market cap of $7.1 billion and is part of the health care sector. Shares are up 440.3% year to date as of the close of trading on Thursday. Currently there are 5 analysts that rate Intercept Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Intercept Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share and deteriorating net income.

On the positive front, Aoxing Pharmaceutical Company ( AXN), up 15.4%, La Jolla Pharmaceutical ( LJPC), up 11.6%, Nanoviricides ( NNVC), up 10.9% and Tekmira Pharmaceuticals Corporation ( TKMR), up 8.1% , were all gainers within the drugs industry with Sanofi ( SNY) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Aldeyra Leaps on Data for Dry Eye Disease Treatment - Biotech Movers

Clovis Sell-Off May Be Overdone